Please login to the form below
Big pharma limits deliveries to Greece
A number of big pharma, including Roche and Sanofi, have started limiting drug deliveries to some hospitals in Greece because of unpaid bills, according to the UK newspaper the Times
A number of big pharma, including Roche and Sanofi, have started limiting drug deliveries to some hospitals in Greece because of unpaid bills, according to the UK newspaper the Times.
The newspaper reported that Roche has halted deliveries to public hospitals that have not paid their bills since September. However, the Swiss company will continue to supply medicines it considers to be life-saving, the Times said.
GlaxoSmithKline told PMLiVE that it is in talks with the Greek government, but will not halt deliveries.
Nycomed may also suspend deliveries if the situation worsens, according to the Times.
Nycomed, Roche and Sanofi were unavailable to comment at the time of writing.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Publications Director
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Senior Medical Writer
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Management
-
Competitive Salary Offered
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
- AZ, Amgen file first-in-class asthma drug with the FDA
- bluebird bio aiming to separate business units by year-end
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- New trial data for Keytruda in triple-negative breast cancer
- Merck & Co reveals plans for women’s health spinoff Organon
- US backs proposal to waive IP protection for COVID-19 vaccines
- bluebird bio aiming to separate business units by year-end
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Sanofi patent case win holds off generic rivals for key cancer drug
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
